Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POEM: EMP16 Dose-Escalation with Vi-Siblin S
NCT06993428Phase 2Not yet recruiting
- Sponsor
- Empros Pharma
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
A Phase 2 trial of EMP16 in obesity, Overweight, sponsored by Empros Pharma. Planned start May 2025; status: not yet recruiting.
02
Drugs
EMP16
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06993428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993428.